Clinical Trial Update: Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing histopathological response to the FOLFOXIRI plus bevacizumab regimen in patients with peritoneal metastasis from colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Peritoneal Metastasis

Drugs mentioned

• Bevacizumab (bevacizumab)
• FOLFOXIRI regimen (FOLFOXIRI)

Snippet

Sponsor: Medical University of Vienna | Conditions: Colorectal Cancer, Peritoneal Metastasis | Phase 2 | Status: UNKNOWN